These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 20941592)

  • 1. Small-molecule inhibitors reveal a new function for Bcl-2 as a proangiogenic signaling molecule.
    Zeitlin BD; Nör JE
    Curr Top Microbiol Immunol; 2011; 348():115-37. PubMed ID: 20941592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small molecule inhibitors of bcl-2 family proteins for pancreatic cancer therapy.
    Masood A; Azmi AS; Mohammad RM
    Cancers (Basel); 2011 Jun; 3(2):1527-49. PubMed ID: 21760983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expanding circle of inhibition: small-molecule inhibitors of Bcl-2 as anticancer cell and antiangiogenic agents.
    Zeitlin BD; Zeitlin IJ; Nör JE
    J Clin Oncol; 2008 Sep; 26(25):4180-8. PubMed ID: 18757333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Attacking cancer's Achilles heel: antagonism of anti-apoptotic BCL-2 family members.
    Opferman JT
    FEBS J; 2016 Jul; 283(14):2661-75. PubMed ID: 26293580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell Death Pathways in Lymphoid Malignancies.
    Fletcher L; Nabrinsky E; Liu T; Danilov A
    Curr Oncol Rep; 2020 Jan; 22(1):10. PubMed ID: 31989308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sunitinib induces apoptosis in pheochromocytoma tumor cells by inhibiting VEGFR2/Akt/mTOR/S6K1 pathways through modulation of Bcl-2 and BAD.
    Saito Y; Tanaka Y; Aita Y; Ishii KA; Ikeda T; Isobe K; Kawakami Y; Shimano H; Hara H; Takekoshi K
    Am J Physiol Endocrinol Metab; 2012 Mar; 302(6):E615-25. PubMed ID: 21878661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of anti-angiogenic tyrosine kinases inhibitors: molecular structures and binding modes.
    Zhang J; Zhang L; Wang Y; Zhao G
    Cancer Chemother Pharmacol; 2016 May; 77(5):905-26. PubMed ID: 26781310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Next Generation of Targeted Molecules for Non-Hodgkin Lymphomas: Small-Molecule Inhibitors of Intracellular Targets and Signaling Pathways.
    Choe H; Ruan J
    Oncology (Williston Park); 2016 Sep; 30(9):847-58. PubMed ID: 27633417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Importance of functional groups in predicting the activity of small molecule inhibitors for Bcl-2 and Bcl-xL.
    Kanakaveti V; Sakthivel R; Rayala SK; Gromiha MM
    Chem Biol Drug Des; 2017 Aug; 90(2):308-316. PubMed ID: 28112863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiangiogenic effect of TW37, a small-molecule inhibitor of Bcl-2.
    Zeitlin BD; Joo E; Dong Z; Warner K; Wang G; Nikolovska-Coleska Z; Wang S; Nör JE
    Cancer Res; 2006 Sep; 66(17):8698-706. PubMed ID: 16951185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibiting the inhibitors: Targeting anti-apoptotic proteins in cancer and therapy resistance.
    Shahar N; Larisch S
    Drug Resist Updat; 2020 Sep; 52():100712. PubMed ID: 32599435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tetramethylpyrazine attenuates carbon tetrachloride-caused liver injury and fibrogenesis and reduces hepatic angiogenesis in rats.
    Zhao S; Zhang Z; Qian L; Lin Q; Zhang C; Shao J; Zhang F; Zheng S
    Biomed Pharmacother; 2017 Feb; 86():521-530. PubMed ID: 28024287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting apoptosis pathways for new cancer therapeutics.
    Bai L; Wang S
    Annu Rev Med; 2014; 65():139-55. PubMed ID: 24188661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The chemical biology of apoptosis: Revisited after 17 years.
    Yang S; Mao Y; Zhang H; Xu Y; An J; Huang Z
    Eur J Med Chem; 2019 Sep; 177():63-75. PubMed ID: 31129454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An inhibitor of Bcl-2 family proteins induces regression of solid tumours.
    Oltersdorf T; Elmore SW; Shoemaker AR; Armstrong RC; Augeri DJ; Belli BA; Bruncko M; Deckwerth TL; Dinges J; Hajduk PJ; Joseph MK; Kitada S; Korsmeyer SJ; Kunzer AR; Letai A; Li C; Mitten MJ; Nettesheim DG; Ng S; Nimmer PM; O'Connor JM; Oleksijew A; Petros AM; Reed JC; Shen W; Tahir SK; Thompson CB; Tomaselli KJ; Wang B; Wendt MD; Zhang H; Fesik SW; Rosenberg SH
    Nature; 2005 Jun; 435(7042):677-81. PubMed ID: 15902208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current overview on the clinical update of Bcl-2 anti-apoptotic inhibitors for cancer therapy.
    Suvarna V; Singh V; Murahari M
    Eur J Pharmacol; 2019 Nov; 862():172655. PubMed ID: 31494078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sialic acid as a target for the development of novel antiangiogenic strategies.
    Chiodelli P; Urbinati C; Paiardi G; Monti E; Rusnati M
    Future Med Chem; 2018 Dec; 10(24):2835-2854. PubMed ID: 30539670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small-molecule BH3 mimetics to antagonize Bcl-2-homolog survival functions in cancer.
    Goldsmith KC; Hogarty MD
    Curr Opin Investig Drugs; 2009 Jun; 10(6):559-71. PubMed ID: 19513945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TW-37, a small-molecule inhibitor of Bcl-2, mediates S-phase cell cycle arrest and suppresses head and neck tumor angiogenesis.
    Ashimori N; Zeitlin BD; Zhang Z; Warner K; Turkienicz IM; Spalding AC; Teknos TN; Wang S; Nör JE
    Mol Cancer Ther; 2009 Apr; 8(4):893-903. PubMed ID: 19372562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging Bcl-2 inhibitors for the treatment of cancer.
    Azmi AS; Wang Z; Philip PA; Mohammad RM; Sarkar FH
    Expert Opin Emerg Drugs; 2011 Mar; 16(1):59-70. PubMed ID: 20812891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.